| CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease (NCT05257967) | British Columbia Cancer Agency | 2022-07-18 |
| Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations (NCT05258279) | Juntendo University | 2022-07-01 |
| Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO) (NCT05382728) | TYK Medicines, Inc | 2022-06-08 |
| Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC (NCT05244213) | Guangdong Provincial People's Hospital | 2022-06-04 |
| Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation (NCT05146219) | TYK Medicines, Inc | 2022-04-02 |
| (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations (NCT05241873) | Blueprint Medicines Corporation | 2022-03-04 |
| (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC (NCT05153408) | Blueprint Medicines Corporation | 2022-01-13 |
| Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid Model (NCT05136014) | Central Hospital, Nancy, France | 2021-11-01 |
| Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC (NCT04989322) | Dr Joanne CHIU | 2021-10-05 |
| Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis (NCT04944069) | Second Affiliated Hospital of Nanchang University | 2021-07-01 |
| (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC (NCT04862780) | Blueprint Medicines Corporation | 2021-06-29 |
| SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs (NCT04764214) | Fudan University | 2021-03-01 |
| Plasma Exosomes Reveal the Efficacy of Targeted Therapy in Patients With EGFR Mutation in Lung Adenocarcinoma (NCT06730477) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2021-01-01 |
| Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC (NCT04768491) | Peking Union Medical College | 2020-09-01 |
| A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC (NCT04636593) | First People's Hospital of Hangzhou | 2020-08-01 |
| Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation (NCT04233021) | Intergroupe Francophone de Cancerologie Thoracique | 2020-07-16 |
| Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb NSCLC With EGFR Activating Mutation (NCT04470076) | Fifth Affiliated Hospital, Sun Yat-Sen University | 2020-07-10 |
| Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis (NCT04148898) | Second Affiliated Hospital of Nanchang University | 2019-11-01 |
| Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study (NCT04122833) | Konkuk University Medical Center | 2019-09-30 |
| Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors (NCT03647956) | The University of Hong Kong | 2018-10-01 |
| Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer (NCT04425681) | Second Affiliated Hospital of Nanchang University | 2017-10-01 |
| Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer (NCT02846792) | University of Washington | 2017-06-14 |
| Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations (NCT02949843) | Wake Forest University Health Sciences | 2017-03-10 |
| EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression (NCT03544814) | Shanghai Chest Hospital | 2015-01-01 |
| Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC (NCT02299765) | Sichuan University | 2014-12-01 |